^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LOAd732

    i
    Other names: LOAd732
    Associations

    News

    Trials
    Company:
    Lokon
    Drug class:
    IL-2 stimulant, CD137 stimulant, CD40L modulator
    Related drugs:
    Associations

    News

    Trials
    over1year
    Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. (PubMed, J Transl Med)
    LOAd732 is a novel immunostimulatory gene therapy based on an oncolytic adenovirus that expresses three transgenes, which are essential for mediating an anti-tumor immune response by activating DCs and stimulating T and NK cells even under imunosuppressive conditions commonly present in the TME. These qualities make LOAd732 an appealing new immunotherapy approach.
    Journal • IO biomarker • Gene therapy
    |
    IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • CD40 (CD40 Molecule) • CD40LG (CD40 ligand)
    |
    IL2 expression
    |
    LOAd732